China Sxt Pharmaceuticals Stock Current Valuation
| SXTC Stock | USD 0.39 0.01 2.63% |
Valuation analysis of China SXT Pharmaceuticals helps investors to measure China SXT's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, China SXT's Enterprise Value Multiple is projected to increase slightly based on the last few years of reporting. Fundamental drivers impacting China SXT's valuation include:
Price Book 0.1118 | Enterprise Value -7.9 M | Enterprise Value Ebitda (0.36) | Price Sales 0.8215 | Enterprise Value Revenue 0.4132 |
Overvalued
Today
Please note that China SXT's price fluctuation is out of control at this time. Calculation of the real value of China SXT Pharmaceuticals is based on 3 months time horizon. Increasing China SXT's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since China SXT is currently traded on the exchange, buyers and sellers on that exchange determine the market value of China Stock. However, China SXT's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.39 | Real 0.37 | Hype 0.39 | Naive 0.35 |
The real value of China Stock, also known as its intrinsic value, is the underlying worth of China SXT Pharmaceuticals Company, which is reflected in its stock price. It is based on China SXT's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of China SXT's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of China SXT Pharmaceuticals helps investors to forecast how China stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of China SXT more accurately as focusing exclusively on China SXT's fundamentals will not take into account other important factors: China SXT Pharmaceuticals Company Current Valuation Analysis
China SXT's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current China SXT Current Valuation | (7.87 M) |
Most of China SXT's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, China SXT Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
China Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for China SXT is extremely important. It helps to project a fair market value of China Stock properly, considering its historical fundamentals such as Current Valuation. Since China SXT's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of China SXT's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of China SXT's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, China SXT Pharmaceuticals has a Current Valuation of (7.87 Million). This is 100.05% lower than that of the Personal Care Products sector and significantly lower than that of the Consumer Staples industry. The current valuation for all United States stocks is 100.05% higher than that of the company.
China Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses China SXT's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of China SXT could also be used in its relative valuation, which is a method of valuing China SXT by comparing valuation metrics of similar companies.China SXT is currently under evaluation in current valuation category among its peers.
China Fundamentals
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0497 | ||||
| Profit Margin | (1.61) % | ||||
| Operating Margin | 7.34 % | ||||
| Current Valuation | (7.87 M) | ||||
| Shares Outstanding | 4.06 M | ||||
| Shares Owned By Insiders | 16.94 % | ||||
| Shares Owned By Institutions | 1.34 % | ||||
| Number Of Shares Shorted | 105.3 K | ||||
| Price To Earning | 5.73 X | ||||
| Price To Book | 0.11 X | ||||
| Price To Sales | 0.82 X | ||||
| Revenue | 1.93 M | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (2.35 M) | ||||
| Net Income | (3.1 M) | ||||
| Cash And Equivalents | 15.52 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 2.65 M | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 1.31 X | ||||
| Book Value Per Share | 6.28 X | ||||
| Cash Flow From Operations | (1.93 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (3.57) X | ||||
| Number Of Employees | 75 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 1.58 M | ||||
| Total Asset | 23.13 M | ||||
| Retained Earnings | (24.71 M) | ||||
| Working Capital | 5.33 M | ||||
| Net Asset | 23.13 M |
About China SXT Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze China SXT Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China SXT using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China SXT Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:Check out China SXT Piotroski F Score and China SXT Altman Z Score analysis. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (3.57) | Revenue Per Share 2.223 | Quarterly Revenue Growth 0.295 | Return On Assets (0.05) |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.